The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

PURPOSE: Androgen receptor (AR) expression occurs in up to 86% of human epidermal growth factor receptor 2-positive (HER2+) breast cancers. In vitro, AR inhibitors enhance antitumor activity of trastuzumab, an anti-HER2 antibody, in trastuzumab-resistant HER2+ cell lines. This open-label, single-arm...

Descripción completa

Detalles Bibliográficos
Autores principales: Wardley, Andrew, Cortes, Javier, Provencher, Louise, Miller, Kathy, Chien, A. Jo, Rugo, Hope S., Steinberg, Joyce, Sugg, Jennifer, Tudor, Iulia C., Huizing, Manon, Young, Robyn, Abramson, Vandana, Bose, Ron, Hart, Lowell, Chan, Stephen, Cameron, David, Wright, Gail S., Graas, Marie-Pascale, Neven, Patrick, Rocca, Andrea, Russo, Stefania, Krop, Ian E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062601/
https://www.ncbi.nlm.nih.gov/pubmed/33591468
http://dx.doi.org/10.1007/s10549-021-06109-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062601/
https://www.ncbi.nlm.nih.gov/pubmed/33591468
http://dx.doi.org/10.1007/s10549-021-06109-7

Ejemplares similares